Who Paid My Doc
Paul Luetmer
Cardiovascular Disease Wausau, WI
NPI 1689675332 CMS profile 525105
500 Wind Ridge Dr, Wausau, WI 54401
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Paul Luetmer of Wausau, WI.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 70 drugsPart D claims
11,245
Drug cost
$2,830,514
Branded share of claims
26%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 710 | $819,501 | |
| Vyndamax Tafamidis | Brand | 24 | $558,700 | |
| Entresto Sacubitril/Valsartan | Brand | 486 | $557,035 | |
| Jardiance Empagliflozin | Brand | 322 | $356,230 | |
| Xarelto Rivaroxaban | Brand | 180 | $204,495 | |
| Multaq Dronedarone Hcl | Brand | 56 | $76,684 | |
| Repatha Sureclick Evolocumab | Brand | 89 | $64,880 | |
| Praluent Pen Alirocumab | Brand | 31 | $18,966 | |
| Metoprolol Succinate | Generic | 1,245 | $18,214 | |
| Vascepa Icosapent Ethyl | Brand | 24 | $16,071 |
The 10 drugs with the highest cost, of 70 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$222,400
Medicare patients
1,609
Services billed
3,937
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 54% | |
| Heart failure | 44% | |
| Atrial fibrillation | 43% | |
| Arthritis | 43% | |
| Diabetes | 33% | |
| Chronic kidney disease | 30% | |
| Depression | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, octafluoropropane microspheres, per ml Q9956 | Office | 63 | 187 | $5,744 |
| Injection, regadenoson, 0.1 mg J2785 | Office | 121 | 481 | $2,167 |
| Injection, aminophyllin, up to 250 mg J0280 | Office | 22 | 22 | $131 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Cardiovascular Disease in Wisconsin
Subhashish Agarwal
Cardiovascular Disease · Brookfield, WI
Lee Biblo
Cardiovascular Disease · Milwaukee, WI
David Grambow
Cardiovascular Disease · Milwaukee, WI
Joshua Liberman
Cardiovascular Disease · Mequon, WI
Imdad Ahmed
Cardiovascular Disease · Janesville, WI
David Murdock
Cardiovascular Disease · Wausau, WI
Related records
Cardiovascular Disease in Wisconsin
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Wisconsin
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.